Physician profile
Eric E Easey
NPI 1700319076
$532.92
in general payments reported to CMS, 2019-2025
11 companies · $104 in 2025
The $104 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $38.91 · 2021: $49.84 · 2022: $102 · 2023: $122 · 2024: $115 · 2025: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $341.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $168.66 | 2021-2025 | Vraylar |
| Amgen INC. | $107.89 | 2020-2025 | Evenity, Prolia, Otezla |
| Sunovion Pharmaceuticals INC. | $62.13 | 2021-2022 | |
| Lilly USA, LLC | $39.47 | 2020-2024 | Zepbound |
| Novo Nordisk INC | $33.80 | 2023-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $31.85 | 2022 | |
| Viatris Specialty LLC | $27.47 | 2025 | Yupelri |
| Mylan Specialty L.P. | $17.48 | 2024 | Yupelri |
| Sumitomo Pharma America, INC. | $17.39 | 2023 | Gemtesa |
| Biohaven Pharmaceutical Holding Company Ltd. | $14.28 | 2022 | |
| Organogenesis INC. | $12.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Easey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.